Irinotecan Hydrochloride Liposome

DRUG3 trials

Sponsors

Fudan University, Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Biliary Tract CancerLocally Recurrent Rectal Cancer

Phase 2

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

RecruitingNCT07183865

Fudan UniversityLocally Recurrent Rectal Cancer

Start: 2025-03-09End: 2030-03-09Target: 44Updated: 2025-09-19

Phase 3

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Not yet recruitingNCT07582315

Sichuan Baili Pharmaceutical Co., Ltd.Biliary Tract Cancer

Start: 2026-07-01End: 2028-12-01Target: 538Updated: 2026-07-01

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

Not yet recruitingNCT07606599

Sichuan Baili Pharmaceutical Co., Ltd.Biliary Tract Cancer

Start: 2026-05-01End: 2028-12-01Target: 398Updated: 2026-05-26